BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
Open Access
- 27 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 103 (5), 668-675
- https://doi.org/10.1038/sj.bjc.6605736
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Putting Risk Prediction in Perspective: Relative Utility CurvesJNCI Journal of the National Cancer Institute, 2009
- Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancerBMC Cancer, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Reading the prognosis of the individual with breast cancerEuropean Journal of Cancer, 2007
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Expression of luminal and basal cytokeratins in human breast carcinomaThe Journal of Pathology, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998